When to Stop DAPT and Anticoagulation Before PCI
For patients undergoing PCI, do NOT stop DAPT or anticoagulation before the procedure—continue all antithrombotic therapy through PCI. This question appears to reflect a misunderstanding of perioperative management principles, as PCI itself is a vascular intervention that requires maximal antithrombotic protection, not interruption of therapy.
Critical Distinction: PCI is NOT a Surgery Requiring Drug Interruption
The evidence provided addresses stopping antiplatelet therapy before non-cardiac surgeries (dental, dermatologic, ophthalmologic procedures, CABG) 1, 2, not before PCI. These are fundamentally different clinical scenarios:
- Before non-cardiac surgery: Stop P2Y12 inhibitors 3-10 days pre-operatively depending on the agent (clopidogrel 5 days, ticagrelor 3-5 days, prasugrel 7 days) to reduce bleeding risk 2
- Before PCI: Continue all antithrombotic therapy—this is when you NEED maximal platelet inhibition to prevent acute thrombotic complications
The Actual Clinical Scenario: Managing Antithrombotics Around PCI
If the Question is About STARTING Therapy Before PCI:
DAPT preloading (giving both aspirin and P2Y12 inhibitor before PCI) is common practice (79% of cases) but does not independently improve outcomes 3. After adjustment for patient factors, preloading showed no difference in mortality, MACE, or stent thrombosis compared to starting therapy at the time of PCI 3.
If the Question is About STOPPING Therapy After PCI:
This is where the evidence becomes highly relevant and nuanced:
Do NOT stop aspirin within the first 30 days after PCI for ACS—this critical period carries heightened ischemic vulnerability. Early aspirin discontinuation before 30 days was associated with a 2.12-fold increased risk of myocardial infarction without reducing bleeding 4.
Post-PCI DAPT Duration Algorithm
Days 0-30 Post-PCI (Critical Window):
- Continue full DAPT (aspirin + P2Y12 inhibitor)
- Aspirin withdrawal during this period increases MI risk 4
- This represents a period of heightened ischemic vulnerability 4
After 30 Days (1-3 Months):
- Consider aspirin discontinuation with P2Y12 monotherapy in selected patients
- Reduces major bleeding (OR 0.46) and major/minor bleeding (OR 0.43) 5
- Does not increase MACE risk 5, 6
- Caution in ACS patients: Very early discontinuation (<1 month) showed 1.81-fold increased stent thrombosis risk, particularly in higher ischemic risk patients 5
3 Months Post-PCI:
- Aspirin discontinuation at 3 months also reduces bleeding (major bleeding OR 0.59) 5
- Similar MACE outcomes to continued DAPT 5
- May be safer timing for ACS patients given lower stent thrombosis signal
Net Clinical Benefit:
Early aspirin discontinuation (1-3 months) reduces net adverse clinical events (NACE) by 23% (OR 0.77) due to bleeding reduction, without compromising ischemic protection in appropriately selected patients 6
Common Pitfalls to Avoid
- Do not confuse PCI with other surgeries: The perioperative guidelines 1, 2 do NOT apply to PCI itself
- Do not stop aspirin in the first 30 days post-PCI for ACS: This increases MI risk 4
- Do not apply early discontinuation strategies to high-risk ACS patients without careful consideration: Stent thrombosis risk increases with very early (<1 month) aspirin withdrawal 5
Regarding Anticoagulation Before PCI
The provided evidence does not address oral anticoagulation management around PCI. The guideline evidence focuses on warfarin/DOAC management for non-cardiac surgeries 1, which is irrelevant to PCI procedures where anticoagulation is typically continued or even intensified (with procedural heparin/bivalirudin).